AnteoTech Ltd (ASX: ADO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AnteoTech Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$51.40 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.71 billion
Earnings per share
-0.004
Dividend per share
N/A
Year To Date Return
11.76%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AnteoTech Ltd (ASX: ADO)
Latest News
Share Gainers
Why the AnteoTech (ASX:ADO) share price is racing 13% higher today
Healthcare Shares
Ellume is making news and these ASX shares are surging, again
Healthcare Shares
AnteoTech (ASX:ADO) share price lifts as Ellume US sales ramp-up
⏸️ ASX Shares
The 5 best ASX shares of FY21 revealed
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Share Gainers
These 3 ASX biotech shares are all up at least 120% in a year
Share Fallers
Why AnteoTech, Fortescue, Synlait, & TPG shares are tumbling lower
Share Gainers
Why the AnteoTech (ASX:ADO) share price is racing higher
Capital Raising
Why the AnteoTech (ASX:ADO) share price is soaring 9% higher today
Share Gainers
Why AnteoTech, Aristocrat Leisure, BWX, & Xero shares are storming higher
Healthcare Shares
Why the Anteotech (ASX:ADO) share price is soaring 10% today
Share Fallers
Why AnteoTech, Domain, Flight Centre, & Nick Scali are sinking today
Frequently Asked Questions
-
No, AnteoTech does not pay dividends at this time.
-
AnteoTech Ltd listed on the ASX on 7 April 2000.
ADO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AnteoTech Ltd
AnteoTech Ltd (ASX: ADO) is a biotechnology company that uses its globally patented particle surface management technology to develop specialty products and services. The company's two key fields are end-user diagnostic products and battery technology.
Its Life Sciences division is centred around AnteoBind, a product that connects biological and synthetic surfaces. The technology has various applications and also assists other diagnostic researchers in developing new products and medical devices.
Meantime, the company's Energy division uses AnteoX binding technology to boost the performance of silicon-containing anodes delivering increased capacity, extended cycle life, and superior mechanical properties in lithium-ion batteries.
ADO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Jan 2025 | $0.02 | $0.00 | 0.00% | 5,981,432 | $0.02 | $0.02 | $0.02 |
| 02 Jan 2025 | $0.02 | $0.00 | 0.00% | 957,254 | $0.02 | $0.02 | $0.02 |
| 31 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,493,468 | $0.02 | $0.02 | $0.02 |
| 30 Dec 2024 | $0.02 | $0.00 | 0.00% | 953,450 | $0.02 | $0.02 | $0.02 |
| 27 Dec 2024 | $0.02 | $0.00 | 0.00% | 694,583 | $0.02 | $0.02 | $0.02 |
| 24 Dec 2024 | $0.02 | $0.00 | 0.00% | 275,458 | $0.02 | $0.02 | $0.02 |
| 23 Dec 2024 | $0.02 | $0.00 | 0.00% | 2,508,361 | $0.02 | $0.02 | $0.02 |
| 20 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,660,186 | $0.02 | $0.02 | $0.02 |
| 19 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,654,168 | $0.02 | $0.02 | $0.02 |
| 18 Dec 2024 | $0.02 | $0.00 | 0.00% | 2,101,209 | $0.02 | $0.02 | $0.02 |
| 17 Dec 2024 | $0.02 | $0.00 | 0.00% | 8,723 | $0.02 | $0.02 | $0.02 |
| 16 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,229,237 | $0.02 | $0.02 | $0.02 |
| 13 Dec 2024 | $0.02 | $0.00 | 0.00% | 8,797,077 | $0.02 | $0.02 | $0.02 |
| 12 Dec 2024 | $0.02 | $0.00 | 0.00% | 6,072,888 | $0.02 | $0.02 | $0.02 |
| 11 Dec 2024 | $0.02 | $0.00 | 0.00% | 2,209,630 | $0.02 | $0.02 | $0.02 |
| 10 Dec 2024 | $0.02 | $0.00 | 0.00% | 3,601,753 | $0.02 | $0.02 | $0.02 |
| 09 Dec 2024 | $0.02 | $0.00 | 0.00% | 3,505,584 | $0.02 | $0.02 | $0.02 |
| 06 Dec 2024 | $0.02 | $0.00 | 0.00% | 12,300,015 | $0.02 | $0.02 | $0.02 |
| 05 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,535,600 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 16 Dec 2024 | Katherine Woodthorpe | Issued | 80,000 | $1,600 |
Rights issue.
|
| 16 Dec 2024 | Geoffrey Cumming | Issued | 1,000,000 | $20,000 |
Rights issue.
|
| 16 Dec 2024 | Glenda McLoughlin | Issued | 118,750 | $2,375 |
Rights issue.
|
| 16 Dec 2024 | David Radford | Issued | 517,816 | $10,356 |
Rights issue.
|
| 16 Dec 2024 | Ewen Crouch | Issued | 443,750 | $8,875 |
Rights issue.
|
| 26 Nov 2024 | David Radford | Issued | 10,800,000 | $216,000 |
Issue of options.
|
| 02 Oct 2024 | David Radford | Buy | 754,007 | $16,588 |
On-market trade.
|
| 13 Sep 2024 | David Radford | Issued | 2,820,000 | $62,040 |
Conversion of securities.
|
| 04 Sep 2024 | David Radford | Expiry | 829,200 | $19,071 |
Options expired.
|
| 31 May 2024 | Geoffrey Cumming | Issued | 600,000 | $14,400 |
Participation in share purchase plan.
|
| 31 May 2024 | Geoffrey Cumming | Buy | 1,200,000 | $30,000 |
Placement.
|
| 31 May 2024 | Katherine Woodthorpe | Issued | 400,000 | $9,600 |
Participation in share purchase plan.
|
| 31 May 2024 | Katherine Woodthorpe | Buy | 800,000 | $20,000 |
Placement.
|
| 31 May 2024 | Ewen Crouch | Buy | 2,000,000 | $50,000 |
Placement.
|
| 31 May 2024 | Ewen Crouch | Issued | 1,000,000 | $24,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Katherine Leslie Woodthorpe | Non-Executive Director | Sep 2021 |
Dr Woodthorpe is a Chair and Non-Executive Director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a record in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. She is also a member of the Risk Committee.
|
| Dr Geoffrey James Cumming | Non-Executive Director | Apr 2009 |
Dr Cumming has over 20 years of experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and on the Board. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss-making business to one achieving over 30% compound annual growth over a four-year period and the profitability levels in Roche's global organisation. He was also Managing Director and CEO of Biosceptre Ltd, an Australian-based biotechnology company commercialising a range of products in cancer diagnosis and treatment. He is member of the Risk Committee and Clinical Advisory Board.
|
| Ms Glenda McLoughlin | Non-Executive Director | Sep 2021 |
Ms McLoughlin has commercial experience as a senior investment banker, commercial advisor and founder. She has over 20 years of experience on listed company boards. In her executive career she held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. She is also Chair of the Risk Committee.
|
| Mr Richard Shubrick Martin | Non-Executive Director | Sep 2005 |
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
|
| Mr David John Radford | Chief Executive OfficerManaging Director | Oct 2022 |
Mr Radford has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits. He has experience managing and communicating with multiple stakeholders from his experience across public capital markets, private companies and working directly with private equity investors. He is member of the Risk Committee.
|
| Mr Ewen Graham Wolseley Crouch | Non-Executive ChairmanNon-Executive Director | Apr 2022 |
Mr Crouch was a Partner at Allens from 1998 to 2013 where his roles included Chairman of Partners, Co-Head Mergers and Acquisitions and Equity Capital Markets, Executive Partner - Asian Offices and Deputy Managing Partner, as well as 11 years of service on its board. He served as a Director of Mission Australia between 1995 and 2016, including 7 years as its Chairman. Ewen served as a Non-Executive Director of Westpac Banking Corporation from 2013 to 2019. He is also a member of the Risk Committee.
|
| Mr Andrew Cook | Company Secretary | Aug 2023 |
-
|
| Katrina Byrne | Chief Operating Officer |
-
|
|
| Andrew Cook | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Levenson Investments Pty Ltd | 62,500,000 | 2.53% |
| Marcolongo Nominees Pty Ltd | 57,505,701 | 2.33% |
| First Cape Management Pty Ltd | 55,195,509 | 2.24% |
| Addison Lake Quality Hire Pty Limited | 38,844,879 | 1.57% |
| BNP Paribas Noms Pty Ltd | 35,212,229 | 1.43% |
| Fossil Super Pty Ltd | 30,100,000 | 1.22% |
| Mr Peter Frederick Kemmis | 27,090,676 | 1.10% |
| Bond Street Custodians Limited | 26,267,749 | 1.06% |
| Mr Anthony William Olding & Mrs Caroline Anne Olding | 24,617,142 | 1.00% |
| Marcolongo Nominees Pty Ltd i | 23,356,544 | 0.95% |
| AWO & CAO Investments Pty Ltd | 23,050,000 | 0.93% |
| Computer Visions Pty Ltd | 22,132,994 | 0.90% |
| Mcrae Superannuation Pty Ltd | 22,125,000 | 0.90% |
| BNP Paribas Nominees Pty Ltd | 21,915,497 | 0.89% |
| Mrs Mary Curtis | 19,617,450 | 0.79% |
| Terry & Linden Deavin Super Pty Ltd | 18,409,284 | 0.75% |
| HSBC Custody Nominees (Australia) Limited | 17,857,374 | 0.72% |
| Mr Claus Kurt Dzalakowski | 17,000,000 | 0.68% |
| Mr Richard Shubrick Martin & Mrs Fiona Diana Martin | 16,862,514 | 0.68% |
| Mrs Elaine Janice Salisbury | 15,400,000 | 0.62% |
